Overall rank by patents
#43,550
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Tianjin Hemay Pharmaceutical Co., Ltd.
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
5
CPC technology areas
27.8
Avg claims per patent
-
5-year filing velocity
The verdict
Tianjin holds 6 US patents across 5 technology areas, rank #43,550 of 50,000 tracked assignees.
- #43,550
- of 50,000 US assignees by volume
- Top 14%
- by Innovation Score (49.6/100)
- 27.8
- avg claims per patent
Portfolio overview
Tianjin Hemay Pharmaceutical Co., Ltd. has been granted 6 US utility patents between 2020 and 2025, placing Tianjin Hemay Pharmaceutical Co., Ltd. at rank #43,550 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 27.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Tianjin Hemay Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Tianjin sits between Thrane & Thrane A/s (6 patents, rank #43,546) and TIV, Inc. (6 patents, rank #43,554) - the closest US assignees by grant volume. The composite Innovation Score of 49.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Tianjin Hemay Pharmaceutical Co., Ltd.'s 27.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Tianjin Hemay Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.
Who files at Tianjin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Thrane & Thrane A…
THRANE & THRANE A/S
6 patents
- Thubrikar Aortic…
THUBRIKAR AORTIC VALVE, INC.
6 patents
- Thurne-middleby
THURNE-MIDDLEBY LTD
6 patents
- Thyssenkrupp Roth…
THYSSENKRUPP ROTHE ERDE GERMANY GMBH
6 patents
- Tien-i Industrial
TIEN-I INDUSTRIAL CO., LTD.
6 patents
- Tiinlab
TIINLAB CORPORATION
6 patents
- Tip-top COM
TIP-TOP.COM LTD
6 patents
- TIV
TIV, INC.
6 patents
- Tianjin Hemay Pha… ◀
TIANJIN HEMAY PHARMACEUTICAL CO., LTD.
6 patents
What this shows Tianjin holds 6 patents at rank #43,550, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Tianjin
By rank, the assignees closest to #43,550 in granted patent volume.
- Thrane & Thrane A/s #43,546 · 6 patents
- Thubrikar Aortic Valve, Inc. #43,547 · 6 patents
- Thurne-middleby Ltd #43,548 · 6 patents
- Thyssenkrupp Rothe ERDE Germany Gmbh #43,549 · 6 patents
- Tien-i Industrial Co., Ltd. #43,551 · 6 patents
- Tiinlab Corporation #43,552 · 6 patents
- Tip-top.com Ltd #43,553 · 6 patents
- TIV, Inc. #43,554 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Tianjin's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Tianjin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 16.7% |
| 2022 | 2 | 33.3% |
| 2023 | 1 | 16.7% |
| 2024 | 1 | 16.7% |
| 2025 | 1 | 16.7% |
Which technologies does Tianjin Hemay Pharmaceutical Co., Ltd. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Tianjin Hemay Pharmaceutical Co., Ltd. hold?
Tianjin Hemay Pharmaceutical Co., Ltd. holds 6 US granted patents filed between 2020 and 2025, spanning 5 technology areas.
What is Tianjin Hemay Pharmaceutical Co., Ltd.'s Innovation Score?
Tianjin Hemay Pharmaceutical Co., Ltd. has an Innovation Score of 49.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Tianjin Hemay Pharmaceutical Co., Ltd. focus on?
Tianjin Hemay Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 5 CPC subclasses total.
Is Tianjin Hemay Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Tianjin Hemay Pharmaceutical Co., Ltd..
What does claim depth mean for Tianjin Hemay Pharmaceutical Co., Ltd.'s patents?
Tianjin Hemay Pharmaceutical Co., Ltd.'s patents average 27.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Tianjin Hemay Pharmaceutical Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Tianjin's 6 grants land it in the top 14% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Tianjin ranks #43,550 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.